Liquidia to Pay $380.7 Million to Settle United Therapeutics Lawsuits
Liquidia said it reached an agreement with United Therapeutics that resolves all pending litigation between the companies. The $380.7 million will be paid in multiple installments this year and next.
Story updates
10:54:12 PM UTC
SquawkNews
LQDA 40 hit! Fully resolves all six ongoing lawsuits between the companies Maintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH) Liquidia to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation against United Therapeutics Strong financial position with $222.7 million in Q3'26 YUTREPIA net product sales (preliminary, unaudited), contributing to $396.1 million in cash and cash equivalents as of September 30, 2026 Liquidia will continue to advance YUTREPIA and L606 clinical programs as previously outlined
Liquidia said it has reached a settlement with United Therapeutics that resolves all pending litigation between the companies. 7 million in multiple installments this year and next. The settlement also includes payments to resolve…